<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052362</url>
  </required_header>
  <id_info>
    <org_study_id>M14-229</org_study_id>
    <secondary_id>2013-003685-14</secondary_id>
    <nct_id>NCT02052362</nct_id>
  </id_info>
  <brief_title>Bioavailability of ABT-450 and ABT-267 With Ritonavir</brief_title>
  <official_title>A Phase I, Open-Label, Single Centre Study Designed to Determine the Absolute Bioavailability of ABT-450 (150 mg) and ABT-267 (25 mg) When Administered as an Oral Co-Formulated Product With Ritonavir (100 mg), ABT 450/r/ABT 267, to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the fraction of ABT-267 and ABT-450 absorbed by the body when given in
      combination with each other and Ritonavir(r).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Absolute bioavailability of ABT-267 and ABT-450 in the body when given together
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute bioavailability</measure>
    <time_frame>Day 1 until 72 hours after single dose of ABT-450/r/ABT-267</time_frame>
    <description>dose normalized AUC(0-inf) for oral dose/dose normalized AUC(0-inf) for IV dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Labs</measure>
    <time_frame>Day -1 until 72 hours after single dose of ABT-450/r/ABT-267</time_frame>
    <description>Chemistry, Haematology, Urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiograms (ECGs)</measure>
    <time_frame>Day-1 until 24 hours after single dose of ABT-450/r/ABT-267</time_frame>
    <description>The measure of any change in 12 lead electrocardiogram from Day-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Screening until 7 days after single dose of ABT-450/r/ABT-267</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Exam</measure>
    <time_frame>Day-1 until 72 hours after single dose ABT-450/r/ABT-267</time_frame>
    <description>To examine any change from Day-1 in the subject's physical presentation (body temperature, blood pressure, pulse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Absolute Bioavailability</condition>
  <arm_group>
    <arm_group_label>Group 1 - Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/r/ABT-267</intervention_name>
    <description>ABT-450, ABT-267 and ritonavir</description>
    <arm_group_label>Group 1 - Regimen A</arm_group_label>
    <arm_group_label>Group 2 - Regimen B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males or non-pregnant, non-lactating healthy females

          2. Body mass index of 18.0 to 30.0 kg/m2

          3. Must be willing and able to communicate and participate in the whole study

          4. Must provide written informed consent

          5. Must agree to use an adequate method of contraception

          6. In a condition of general good health, based upon the results of a medical history,
             physical examination, vital signs, laboratory profile and a 12-lead ECG

        Exclusion Criteria:

          1. Participation in a clinical research study within the previous 3 months or in an
             absorption, distribution, metabolism, and excretion (ADME) study within the previous
             12 months

          2. History of any drug or alcohol abuse in the past 2 years or current smokers and those
             who have smoked within the last 12 months or a positive cotinine urine test at
             screening and admission

          3. Radiation exposure, including that from the present study, excluding background
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,
             as defined in the Ionising Radiation Regulations 1999, shall participate in the study

          4. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

          5. Donation or loss of greater than 550 mL of blood (including plasmapheresis) or receipt
             of a transfusion of any blood product within the previous 8 weeks

          6. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or
             herbal remedies within the 14 days or any drug by injection (including vaccines)
             within 30 days or within 10 half-lives of the respective medication, whichever is
             longer, before Investigational Medical Product (IMP) administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armen Asatryan, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118615</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>February 17, 2014</last_update_submitted>
  <last_update_submitted_qc>February 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>absolute bioavailability</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

